Anti-TAB-2 Antibody, clone 1D5.2 clone 1D5.2, from mouse

TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 (UniProt: Q9NYJ8; also known as Mitogen-activated protein kinase kinase kinase 7-interacting protein 2, TAK1-binding protein 2, TAB-2, TGF-beta-activated kinase 1-binding protein 2) is encoded by the TAB2 (also known as KIAA0733, MAP3K7IP2) gene (Gene ID: 23118) in human. TAB-2 is a peripheral membrane protein that serves as an adapter protein that links MAP3K7/TAK1 and TRAF6. Two isoforms of TAB-2 have been reported that are produced by alternative splicing. TAB-2 promotes MAP3K7 activation in the IL-1 signaling pathway. Following IL-1 stimulation it translocates from the membrane to cytosol. TAB-2 is widely expressed. In the embryo, it is expressed in the ventricular trabeculae, endothelial cells of the conotruncal cushions of the outflow tract and in the endothelial cells lining the developing aortic valves. TAB-2 contains a RanBP2-type zinc finger domain (aa 663-693) that mediates binding to two consecutive Lysine 63-linked ubituitins. The binding of Lysine 63-linked polyubiquitin chains to TAB-2 promotes autophosphorylation of MAP3K7 at Threonine 187. Mutations in TAB2 gene are reported to cause multiple congenital heart defects characterized by congenital developmental abnormalities involving structures of the heart, including left ventricular outflow tract obstruction, sub-aortic stenosis, atrial fibrillation, bicuspid aortic valve and aortic dilation.